Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, acquires Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. Mallinckrodt plc entered into debt financing commitments with affiliates of Deutsche Bank Securities Inc. VISCHER advises Mallincrodt on the Swiss law aspects of the financing. The Vischer team is lead by Matthias Staehelin and Adrian Dörig (both Corporate), Christoph Niederer (Tax) and includes Marius Meier and Janusz Marty.